Trending

ovarian

Cancer market commentary: 3 highlights from ESMO (Part 1)

Cancer market commentary: 3 highlights from ESMO (Part 1)

Commentary on key cancer data from ESMO by Stephanie Hawthorne

X

Cancer market commentary: 3 highlights from ESMO (Part 1)

https://pharmaphorum.com/esmo-2016/cancer-market-commentary-3-highlights-esmo-conference-part-1/

Eye on ESMO: Day 2 – gamechangers take centre stage

Eye on ESMO: Day 2 – gamechangers take centre stage

Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise

X

Eye on ESMO: Day 2 – gamechangers take centre stage

https://pharmaphorum.com/esmo-2016/eye-esmo-day-two-gamechangers-take-centre-stage/

Clovis files key ovarian cancer drug in US

Clovis files key ovarian cancer drug in US

Rucaparib is only drug left in biotech’s pipeline.

X

Clovis files key ovarian cancer drug in US

https://pharmaphorum.com/news/clovis-files-key-ovarian-cancer-drug-us/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com